Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Graham J, Johnson K, Jiang Y, Weiss T. Comparing the estimated potential health impact of 2 herpes zoster vaccines in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.
Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ. Budget-impact analysis of alternative herpes zoster vaccine strategies: a U.S. HMO perspective. J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872